Pacira BioSciences, Inc. (PCRX)
USD 24.97
(1.67%)
USD 24.97
(1.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 704.25 Million USD | -22.28% |
| 2022 | 906.19 Million USD | -32.62% |
| 2021 | 1.34 Billion USD | 105.39% |
| 2020 | 654.82 Million USD | 37.53% |
| 2019 | 476.12 Million USD | 29.34% |
| 2018 | 368.12 Million USD | 5.51% |
| 2017 | 348.88 Million USD | 102.27% |
| 2016 | 172.49 Million USD | 0.74% |
| 2015 | 171.23 Million USD | 10.52% |
| 2014 | 154.92 Million USD | 20.5% |
| 2013 | 128.57 Million USD | 178.3% |
| 2012 | 46.19 Million USD | -29.17% |
| 2011 | 65.22 Million USD | -43.26% |
| 2010 | 114.94 Million USD | 71.81% |
| 2009 | 66.9 Million USD | 55.4% |
| 2008 | 43.05 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 691.15 Million USD | -1.86% |
| 2024 Q2 | 767.54 Million USD | 11.05% |
| 2023 Q1 | 755.37 Million USD | -16.64% |
| 2023 Q3 | 702.91 Million USD | -4.29% |
| 2023 Q2 | 734.4 Million USD | -2.78% |
| 2023 FY | 704.25 Million USD | -22.28% |
| 2023 Q4 | 704.25 Million USD | 0.19% |
| 2022 Q3 | 964.24 Million USD | -1.34% |
| 2022 Q4 | 906.19 Million USD | -6.02% |
| 2022 FY | 906.19 Million USD | -32.62% |
| 2022 Q1 | 1.18 Billion USD | -12.12% |
| 2022 Q2 | 977.35 Million USD | -17.31% |
| 2021 Q3 | 637.4 Million USD | -0.2% |
| 2021 FY | 1.34 Billion USD | 105.39% |
| 2021 Q1 | 636.73 Million USD | -2.76% |
| 2021 Q4 | 1.34 Billion USD | 111.0% |
| 2021 Q2 | 638.66 Million USD | 0.3% |
| 2020 Q1 | 447.34 Million USD | -6.04% |
| 2020 Q2 | 477.96 Million USD | 6.85% |
| 2020 Q3 | 635.57 Million USD | 32.98% |
| 2020 Q4 | 654.82 Million USD | 3.03% |
| 2020 FY | 654.82 Million USD | 37.53% |
| 2019 Q3 | 461.32 Million USD | 3.39% |
| 2019 Q4 | 476.12 Million USD | 3.21% |
| 2019 Q2 | 446.19 Million USD | 13.93% |
| 2019 Q1 | 391.63 Million USD | 6.39% |
| 2019 FY | 476.12 Million USD | 29.34% |
| 2018 Q4 | 368.12 Million USD | 2.89% |
| 2018 FY | 368.12 Million USD | 5.51% |
| 2018 Q3 | 357.77 Million USD | 1.59% |
| 2018 Q2 | 352.16 Million USD | 2.52% |
| 2018 Q1 | 343.51 Million USD | -1.54% |
| 2017 Q2 | 344.69 Million USD | 4.67% |
| 2017 Q1 | 329.32 Million USD | 90.93% |
| 2017 Q3 | 341.29 Million USD | -0.99% |
| 2017 FY | 348.88 Million USD | 102.27% |
| 2017 Q4 | 348.88 Million USD | 2.23% |
| 2016 FY | 172.49 Million USD | 0.74% |
| 2016 Q1 | 165.03 Million USD | -3.62% |
| 2016 Q3 | 167 Million USD | -3.1% |
| 2016 Q4 | 172.49 Million USD | 3.28% |
| 2016 Q2 | 172.34 Million USD | 4.43% |
| 2015 Q1 | 151 Million USD | -2.53% |
| 2015 Q4 | 171.23 Million USD | 7.04% |
| 2015 FY | 171.23 Million USD | 10.52% |
| 2015 Q2 | 159.71 Million USD | 5.76% |
| 2015 Q3 | 159.97 Million USD | 0.16% |
| 2014 Q2 | 144.11 Million USD | 12.6% |
| 2014 Q4 | 154.92 Million USD | 3.06% |
| 2014 Q1 | 127.98 Million USD | -0.46% |
| 2014 FY | 154.92 Million USD | 20.5% |
| 2014 Q3 | 150.32 Million USD | 4.31% |
| 2013 Q4 | 128.57 Million USD | 4.29% |
| 2013 FY | 128.57 Million USD | 178.3% |
| 2013 Q3 | 123.27 Million USD | 3.34% |
| 2013 Q2 | 119.28 Million USD | 3.33% |
| 2013 Q1 | 115.44 Million USD | 149.9% |
| 2012 Q4 | 46.19 Million USD | -11.8% |
| 2012 Q1 | 57.02 Million USD | -12.57% |
| 2012 FY | 46.19 Million USD | -29.17% |
| 2012 Q2 | 48.34 Million USD | -15.21% |
| 2012 Q3 | 52.38 Million USD | 8.34% |
| 2011 Q4 | 65.22 Million USD | 2.33% |
| 2011 Q2 | 64.15 Million USD | -3.85% |
| 2011 Q1 | 66.72 Million USD | -41.95% |
| 2011 Q3 | 63.73 Million USD | -0.66% |
| 2011 FY | 65.22 Million USD | -43.26% |
| 2010 Q3 | 95.79 Million USD | 13.4% |
| 2010 FY | 114.94 Million USD | 71.81% |
| 2010 Q4 | 114.94 Million USD | 19.99% |
| 2010 Q2 | 84.47 Million USD | 0.0% |
| 2009 FY | 66.9 Million USD | 55.4% |
| 2009 Q4 | 66.9 Million USD | 0.0% |
| 2008 FY | 43.05 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 25.702% |
| Embecta Corp. | 2.03 Billion USD | 65.412% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -49.31% |
| Dynavax Technologies Corporation | 375.02 Million USD | -87.79% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -6.578% |
| PainReform Ltd. | 2.69 Million USD | -26070.792% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -329.673% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -11370.715% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1170.074% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -7557.777% |
| Cosmos Health Inc. | 30.25 Million USD | -2227.925% |
| Journey Medical Corporation | 56.49 Million USD | -1146.493% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -11370.715% |
| Safety Shot Inc | 3.89 Million USD | -17994.759% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1726.816% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -414.54% |
| Bright Green Corporation | 6.43 Million USD | -10838.876% |
| Procaps Group, S.A. | 462.06 Million USD | -52.415% |
| Theratechnologies Inc. | 98.63 Million USD | -613.973% |
| Harrow Health, Inc. | 241.75 Million USD | -191.312% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -7943.125% |
| Biofrontera Inc. | 23.13 Million USD | -2943.589% |
| DURECT Corporation | 30.4 Million USD | -2216.174% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -44.474% |
| Cronos Group Inc. | 43.73 Million USD | -1510.24% |
| OptiNose, Inc. | 194.33 Million USD | -262.393% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 13.839% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1353.723% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3257.097% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -288.315% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -18569.962% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1241.026% |
| Radius Health, Inc. | 804.29 Million USD | 12.438% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -5020.249% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1555.359% |
| Phibro Animal Health Corporation | 725.54 Million USD | 2.934% |
| Procaps Group S.A. | 462.06 Million USD | -52.415% |
| Alvotech | 1.88 Billion USD | 62.591% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -4922.507% |
| Viatris Inc. | 27.21 Billion USD | 97.413% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2180.474% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -679.225% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1114.71% |
| Tilray Brands, Inc. | 892.11 Million USD | 21.058% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -220.408% |
| Shineco, Inc. | 47.6 Million USD | -1379.477% |
| PetIQ, Inc. | 645.22 Million USD | -9.148% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -320728.019% |
| Incannex Healthcare Limited | 5.83 Million USD | -11979.863% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 30.915% |
| Alimera Sciences, Inc. | 107.35 Million USD | -556.013% |
| Silver Spike Investment Corp. | 3 Million USD | -23298.523% |
| Assertio Holdings, Inc. | 148.41 Million USD | -374.515% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -37044.989% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3203.92% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -9923.57% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8194.605% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -306.176% |
| Hempacco Co., Inc. | 18.82 Million USD | -3641.584% |
| Talphera, Inc. | 6.29 Million USD | -11096.439% |
| Alvotech | 1.88 Billion USD | 62.591% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -308.028% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 15.684% |
| Currenc Group, Inc. | 177.67 Million USD | -296.372% |
| Kamada Ltd. | 109.96 Million USD | -540.417% |
| Indivior PLC | 1.95 Billion USD | 63.907% |
| Evoke Pharma, Inc. | 9.64 Million USD | -7199.44% |
| Flora Growth Corp. | 17.22 Million USD | -3989.281% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8194.605% |
| Evolus, Inc. | 209.68 Million USD | -235.861% |
| HUTCHMED (China) Limited | 536.38 Million USD | -31.296% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 19.375% |
| Akanda Corp. | 12.66 Million USD | -5458.942% |